Lv3
230 积分 2023-10-30 加入
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial
4天前
已完结
Safety and Efficacy of Anti–IL-23 Monoclonal Antibody QX004N for Patients With Psoriasis
4天前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, phase Ⅲ study evaluating the efficacy and safety of Xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis
4天前
已完结
An Oral Interleukin-23–Receptor Antagonist Peptide for Plaque Psoriasis
4天前
已完结
Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study
4天前
已完结
A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis
4天前
已完结
A randomized, double-blind phase III study to demonstrate the clinical similarity of biosimilar SCT630 to reference adalimumab in Chinese patients with moderate to severe plaque psoriasis
4天前
已完结
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results
4天前
已完结
Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta‐analysis‐based comparison of treatment efficacy
26天前
已完结
Long‐term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real‐world, single‐center experience
1个月前
已完结
皖公网安备34019202002308
